

## Validation of the DAPSA with a quick quantitative CRP assay (Q-DAPSA)

**SUPPLEMENTARY DATA***Supplementary Table S1: Pharmacological treatment at the time of study participation.*

|   |                 |
|---|-----------------|
| <b>Systemic glucocorticosteroids, n (%)</b>   | 10 (9.6%)       |
| Mean dosage of prednisolone equivalent per day in mg for all patients receiving glucocorticosteroids $\pm$ SD | 6.3 $\pm$ 4.1   |
| <b>NSAIDs, n (%)</b>  | 43 (41.3%)      |
| Mean NSAID equivalent score $\pm$ SD for patients receiving NSAIDs as medication*                             | 50.0 $\pm$ 41.7 |
| Number of patients with NSAID equivalent score of 100* (%)  | 16 (15.4%)      |
| <b>csDMARDs, n (%)</b>  | 37 (35.6%)      |
| Methotrexate, n (%)   | 33 (31.7%)      |
| Leflunomide, n (%)  | 2 (1.9%)        |
| Sulfasalazine, n (%)  | 2 (1.9%)        |
| <b>tsDMARD, n (%)</b>   | 3 (2.9%)        |
| Apremilast, n (%)   | 2 (1.9%)        |
| Tofacitinib, n (%)  | 1 (1.0%)        |
| <b>bDMARDs, n (%)</b>   | 53 (51.0%)      |
| TNF inhibitors  | 21 (20.2%)      |
| IL-17A inhibitors   | 17 (16.3%)      |
| Ustekinumab, n (%)  | 11 (10.6%)      |
| Guselkumab, n (%)   | 2 (1.9%)        |
| Abatacept, n (%)  | 1 (1.0%)        |
| Rituximab, n (%)  | 1 (1.0%)        |
|   |                 |
| <b>csDMARD monotherapy</b>  | 22 (21.2%)      |
| <b>tsDMARD monotherapy</b>  | 2 (1.9%)        |
| <b>bDMARD monotherapy</b>   | 38 (36.5%)      |
| <b>csDMARDs + bDMARDs combination</b>   | 14 (13.5%)      |
| <b>csDMARDs + tsDMARDs combination</b>  | 1 (1.0%)        |
| <b>No csDMARDs / tsDMARDs and no bDMARDs</b>  | 26 (25.0%)      |

*n* = 104

\*Modified formula for NSAID equivalent score based on Dougados et al.<sup>21</sup>:

NSAID-equivalent-dose  $\times$  (days of intake per week / 7)<sup>21</sup>.

*bDMARDs* = biological DMARDs, *csDMARDs* = conventional synthetic DMARDs, *DMARDs* = disease-modifying antirheumatic drugs, *IL-17* = interleukin-17, *NSAIDs* = non-steroidal anti-inflammatory drugs, *SD* = standard deviation, *TNF* = tumour necrosis factor, *tsDMARDs* = targeted synthetic DMARDs.

## Validation of the DAPSA with a quick quantitative CRP assay (Q-DAPSA)

**Supplementary Table S2: A) Patients with different disease activity categories by Q-DAPSA and DAPSA and B) Patients with different disease activity categories by cDAPSA and DAPSA.**

|          | DAPSA  | Q-DAPSA     | cDAPSA      | SJC | TJC | PtGA | PtPain | Routine laboratory CRP (mg/dL) | qCRP (mg/dL) |
|----------|--|-------------|-------------|-----|-----|------|--------|--------------------------------|--------------|
| <b>A</b> | 13.99 (LDA)  | 14.02 (MDA) | 13.20 (MDA) | 0   | 2   | 4.4  | 6.8    | 0.79                           | 0.82         |
|          | 4.00 (REM)   | 4.20 (LDA)  | 3.50 (REM)  | 0   | 0   | 2.7  | 0.8    | 0.50                           | 0.70         |
| <b>B</b> | Higher disease activity category with cDAPSA than DAPSA: |             |             |     |     |      |        |                                |              |
|          | 27.83 (MDA)  | 27.92 (MDA) | 27.60 (HDA) | 3   | 5   | 9.8  | 9.8    | 0.23                           | 0.32         |
|          | 27.58 (MDA)  | 27.56 (MDA) | 27.10 (HDA) | 2   | 12  | 7.6  | 5.5    | 0.48                           | 0.46         |
|          | 27.51 (MDA)  | 27.60 (MDA) | 27.40 (HDA) | 3   | 10  | 7.2  | 7.2    | 0.11                           | 0.20         |
|          | 13.99 (LDA)  | 14.02 (MDA) | 13.20 (MDA) | 0   | 2   | 4.4  | 6.8    | 0.79                           | 0.82         |
|          | 13.85 (LDA)  | 13.87 (LDA) | 13.70 (MDA) | 0   | 9   | 2.4  | 2.3    | 0.15                           | 0.17         |
|          | Higher disease activity category with DAPSA than cDAPSA: |             |             |     |     |      |        |                                |              |
|          | 16.96 (MDA)  | 17.80 (MDA) | 12.00 (LDA) | 0   | 0   | 5.6  | 6.4    | 4.96                           | 5.80         |
|          | 5.43 (LDA)   | 9.40 (LDA)  | 1.10 (REM)  | 0   | 0   | 1.1  | 0.0    | 4.33                           | 8.30         |

SJC refers to 66 joints, TJC refers to 68 joints. PtGA was assessed on a visual-analogue scale from 0 cm = inactive to 10 cm = very active; PtPain was assessed on a visual-analogue scale from 0 cm = no pain to 10 cm = most severe pain.

cDAPSA = clinical DAPSA, CRP = C-reactive protein, DAPSA = Disease activity index for Psoriatic Arthritis, HDA = high disease activity, LDA = low disease activity, MDA = moderate disease activity, PtGA = patient global assessment, PtPain = patient assessment of pain, qCRP = quick quantitative CRP, Q-DAPSA = DAPSA calculated with a qCRP assay, REM = remission, SJC = swollen joint count, TJC = tender joint count.